Roche: ambitions set out at Pharma Day 2024

(CercleFinance.com) - Roche announced on Monday that it expects its positive sales trajectory to continue into 2025.


This announcement comes as the Swiss biopharmaceutical group saw sales growth jump 9% in the second quarter, above the 5% average annual growth recorded over the last ten years.

At its Pharma Day 2024 event in London today, the company set itself the target of launching 20 "transforming" drugs by 2029 in therapeutic areas with high societal impact.

The company has set out its priorities in 11 diseases, in which it says it is currently investing from start to finish: breast cancer, lung cancer, blood cancers, hemophilia, multiple sclerosis, Alzheimer's disease, chronic bowel disease, COPD, ocular hypertension, DLMA and obesity.

Anticipating that the proportion of the world's population who are overweight or obese will rise from 42% today to 54% in 2035, Roche says it expects the obesity market to exceed the $100 billion mark by 2030.

With regard to the development of new medicines, the Group says it expects to reduce research and development (R&D) costs for new molecular entity (NME) products by 20% by 2030.

For the entire process, from identification of the new molecule to completion of Phase III clinical trials, the company is aiming for a 40% reduction in the development time of its new projects by then.

Copyright (c) 2024 CercleFinance.com. All rights reserved.